Should you buy Sana Biotechnology stock now?
Yes, the technical signal for Sana Biotechnology is currently BUY. Sana Biotechnology trades at $3.85 as of 9/4/2026. The overall technical signal is: Strong Buy. The technical analysis shows the following: MACD is positive (bullish trend) at 0.125 with falling momentum (signal: 0.137); RSI is at 55.5 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $8.43 points to 119.2% upside. The stock is in a broader uptrend (above SMA50/SMA200). This is a technical observation based on current data, not investment advice.
What is the price target for Sana Biotechnology stock?
The average analyst price target for Sana Biotechnology is $8.43. The current price is $3.85, which gives an upside of 119.2%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $7.59 and $9.27.
Is Sana Biotechnology a dividend stock?
No, Sana Biotechnology does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Sana Biotechnology stock?
Sana Biotechnology is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 84.7%, which classifies the stock as Extremely speculative.
Is Sana Biotechnology overvalued?
No, Sana Biotechnology is considered undervalued based on the analyst price target (119.2% upside). Sana Biotechnology has the following valuation ratios: a P/B ratio of 7.4. The analyst price target suggests that the stock is undervalued by 119.2%.
Is Sana Biotechnology overbought?
No, Sana Biotechnology is not overbought. RSI is at 55.5 (neutral zone). The technical indicators show: RSI is at 55.5 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 0.5% above the 20-day average (short-term uptrend). In addition, MACD is positive, but momentum is falling.
When is the next Sana Biotechnology earnings report?
The date of the next earnings report for Sana Biotechnology has not been published yet. Check the company's investor calendar for updates.
Is Sana Biotechnology shorted?
Yes, Sana Biotechnology is shorted with 24.0% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Sana Biotechnology stock?
No, insiders are not buying Sana Biotechnology shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 1 sales. On a net basis, 169,159 $ worth of shares were sold. Across the last 20 reported transactions, the split is 3 purchases and 17 sales, with a net 3,541,195 $ bought. Active sellers include PATEL DHAVALKUMAR DHIRAJLAL, Wyrick Susan D., Harr Steve and others. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Sana Biotechnology a good stock?
Based on our total score, Sana Biotechnology is rated as a disastrous stock with a total score of 14 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Value: 5/100, Quality: 9/100, Momentum: 29/100. In addition: analysts see 119.2% upside to the price target; technical signal: Strong Buy. Whether Sana Biotechnology is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Sana Biotechnology stock?
The outlook for Sana Biotechnology based on current data: the average analyst price target is $8.43 (+119.2%); the stock is in an uptrend (above SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Sana Biotechnology stock moving?
Sana Biotechnology is stable right now. The technical indicators show: the price is close to the 20-day average; short interest is 24.0% (high – many are betting on a decline); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Sana Biotechnology go?
The average analyst price target for Sana Biotechnology is $8.43, which corresponds to a potential gain of 119.2% from the current price of $3.85. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Sana Biotechnology fall?
We lack enough history to give a specific floor for Sana Biotechnology. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Sana Biotechnology do?
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell me... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Sana Biotechnology as an investment.
Did Sana Biotechnology raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Sana Biotechnology. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Sana Biotechnology making money or losing money?
We have no current profitability data for Sana Biotechnology. See the latest report in the earnings history above.
Can Sana Biotechnology go bankrupt?
The bankruptcy risk of Sana Biotechnology is rated as elevated. Altman Z2 (a model for assessing financial distress) is -16.81 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 100% (moderate). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Sana Biotechnology have a lot of debt?
Sana Biotechnology has moderate debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 100%. For the healthcare sector, 80-150% counts as a typical level. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.